India Glycols to Split Into 3 Entities: What Investors Should Know

Spread love

By S. JHA

India Glycols (INDIAGLYCO) is demerging into three listed entities. With NCLT hearing on May 21, here’s the full investor breakdown.

Mumbai, May 15, 2026 — Shares of India Glycols have been steadily inching towards their 52-week high mark amid the stock market volatility. Market participants are keeping a close watch on the stock as the company is heading for a three-way split.

Market participants claim that the story of India Glycols is one of India’s most consequential corporate restructurings. India Glycols Limited — a ₹7,200 crore market-cap specialty chemicals company that has quietly delivered multibagger returns over the past five years — is in the process of splitting itself into three separately listed entities. The NCLT hearing that could greenlight the final stage is scheduled for May 21, 2026.

For investors holding INDIAGLYCO on BSE or NSE, this is not an event to sit out passively. What happens in the next few weeks will determine how hundreds of crores of latent value are unlocked — or not.

Here is everything you need to understand: what the split means, what the numbers say, what the charts are telling you, and critically, what to do with your position.

The Split, Explained Simply

India Glycols is not a simple company. It manufactures glycols, green solvents, bio-polymers, industrial gases, potable spirits, biofuels, and pharmaceutical ingredients from a single balance sheet — a sprawling conglomerate structure that the market has chronically undervalued because no single investor profile fits it cleanly.

The board’s solution, approved in its modified form on May 16, 2025, and now before the NCLT for final sanction, is to separate the three core businesses into three independently listed entities:

India Glycols Limited (Residual IGL)

The surviving parent retains the core specialty chemicals business — Bio-based Specialties, Performance Chemicals, Bio-Glycols, Green Solvents, New Specialty Products, and Industrial Gases. This is the original engine: an industrial chemical manufacturer competing in a sector alongside Tata Chemicals and Deepak Nitrite.

Ennature Bio Pharma Limited (EBL)

The biopharma demerger carves out nutraceuticals, phytochemicals, natural plant-based active pharmaceutical ingredients (APIs), and bio-polymers into a dedicated entity. Ennature already holds a significant achievement: in 2026, the U.S. FDA issued it an Establishment Inspection Report (EIR) with *no observations* — a clean bill of health that validates its manufacturing standards for regulated pharma markets. This entity will compete in a space alongside Biocon and LanzaTech.

IGL Spirits Limited (ISL)

The spirits and biofuel undertaking becomes its own listed company. The division includes potable spirits and ethanol/biofuel manufacturing — a segment that posted 17% year-on-year revenue growth in Q3 FY26, reaching ₹1,025 crore for that quarter alone. Competitors include United Spirits and a broad field of domestic distillers.

According to the Scheme of Arrangement filed with NCLT under Sections 230 to 232 of the Companies Act, 2013 — and as confirmed by market disclosures — all three entities will be listed on both BSE and NSE, enabling full price discovery for each business.

Indian Hospital Stocks 2026: 4 BUY Picks — Sharekhan Report

The Share Entitlement Ratio: What You Will Actually Receive

This is the number every existing shareholder should know cold.

Per the scheme as approved unanimously by shareholders and unsecured creditors on March 24, 2026 (with 4,42,48,625 votes in favour — 100% of voting bloc present:

– For every 3 shares of India Glycols held → 1 share of Ennature Bio Pharma Limited

– For every 1 share of India Glycols held → 1 share of IGL Spirits Limited

The appointed date for the scheme is April 1, 2026 — meaning the restructuring is legally effective from that date, subject to NCLT’s final sanction. The share entitlement valuation was prepared by registered valuer Kshitij Goel, based on financial information of the demerged undertakings up to December 31, 2024.

In practical terms: an investor holding 300 shares of INDIAGLYCO will eventually hold 300 shares of IGL and IGL Spirits each, plus 100 shares of Ennature Bio Pharma. Three securities, three market opportunities, and — if demerger history is a guide — the sum of parts often exceeds the original whole.

The Regulatory Timeline: Where Things Stand Today

The demerger has moved with unusual speed through regulatory checkpoints:

| Milestone | Date |

| Board approves modified demerger scheme | May 16, 2025 |

| NCLT first motion approved | January 15, 2026 |

| Shareholder & creditor meetings (100% approval) | March 24, 2026 |

| Appointed date (effective date of scheme) | April 1, 2026 |

| NCLT second motion admitted | April 9, 2026 |

| Public notices published (Financial Express, Business Standard) | May 5, 2026 |

| NCLT next hearing | May 21, 2026 |

According to ScanX Trade, the NCLT has directed all statutory authorities to submit any representations within 30 days of notice. If no objections are received, it is presumed they have no objections. The May 21 hearing is where the court will assess any such objections before moving toward final sanction.

What this means for timing: Final NCLT sanction could come within weeks of May 21 if objections are minimal or resolved. Listing of the two new entities on NSE and BSE will follow thereafter. A realistic listing window for Ennature Bio Pharma and IGL Spirits is likely H2 FY27 — calendar Q3 2026, at the earliest.

Financials: The Business Is Genuinely Getting Better

The demerger narrative would be less compelling if the underlying numbers were weak. They are not.

Q4 FY26 (Quarter ended March 31, 2026):

India Glycols reported a 35.7% year-on-year rise in consolidated net profit to ₹86.9 crore, as per Free Press Journal, supported by improved profitability across business segments. Revenue from operations rose 7.8% year-on-year to ₹2,360 crore. EBITDA climbed to ₹167.1 crore compared to ₹147.5 crore a year earlier.

Full Year FY26:

Consolidated revenue from operations rose 8.7% to ₹9,826.6 crore from ₹9,039 crore in FY25. Net profit for the year jumped 26.8% to ₹292.8 crore from ₹230.9 crore. Earnings per share for FY26 stood at ₹45.95 against ₹37.29 in FY25, reflecting sharp earnings acceleration.

Q3 FY26 (the standout quarter):

Consolidated EBITDA surged 36.09% year-on-year to ₹176.21 crore, driving margin expansion from 5.34% in Q3 FY25 to 6.91% in Q3 FY26, per Whalesbook. Net profit rose 19% to ₹67.57 crore. Revenue was ₹1,102.40 crore for the quarter.

The long arc: Per Share.Market, the company delivered Q1 FY26 consolidated revenue of ₹2,503.12 crore, up 9.7% year-on-year, with profit after tax rising 21.2% year-on-year. Revenue has grown sequentially for four straight quarters at an average rate of 7.2% per quarter, per IndMoney data.

The balance sheet: Screener.in reports the company carries a promoter holding of 59.6%, annual revenue of ₹4,098 crore on a trailing twelve-month basis, profit of ₹270 crore, and a price-to-book ratio of approximately 2.59. Debt-to-equity stands at a manageable 46%, per 5paisa. Debt was also actively reduced — the Q3 FY26 earnings call noted a reduction of ₹582 crore in debt, with improved interest cost expectations heading into Q4.

Key metrics at a glance:

| Metric | Value |

| Market Cap | ~₹6,200 crore |

| FY26 Revenue | ₹9,826.6 crore |

| FY26 Net Profit | ₹292.8 crore |

| FY26 EPS | ₹45.95 |

| P/E Ratio | ~23.5x |

| P/B Ratio | ~2.5x |

| Debt-to-Equity | ~46% |

| Promoter Holding | 59.6% |

| 5-Year Return | ~510% |

Technicals: A Stock in Consolidation, Watching Its Catalysts

India Glycols has been a multibagger on any meaningful time horizon — five-year returns exceed 510%, per Share.Market. But the near-term technical picture is more nuanced, and worth reading carefully in the context of the demerger.

Current setup (as of May 2026):

The stock is trading at approximately ₹1,085 (price has moved sharply with demerger announcements). Per 5paisa’s technical data, all 16 moving averages tracked are currently bearish. The 20-day EMA stands at ₹1,529.95; the 50-day at ₹1,385.61; the 100-day at ₹1,312.90; and the 200-day at ₹1,232.94. The stock is trading below above all key moving averages — a structurally bearish alignment.

52-week range: ₹679 (52-week low) to ₹1,800 (52-week high) — a range that reflects the demerger-driven re-rating.

The divergence between short-term algorithmic targets and where the stock has recently traded tells you something important: the market is pricing in demerger value that fundamental models built on historical earnings may not fully capture. That’s a double-edged sword — it means further upside requires the demerger to actually deliver, but also that the market believes in the thesis.

The Bull Case: Why the Three-Way Split Could Unlock Significant Value

Demergers in India have a clear track record when done for the right structural reasons. Piramal Enterprises unlocking pharma from financial services, Vedanta’s attempted simplification, Jubilant Life Sciences separating pharma and agri — all share the same thesis: conglomerates trade at a discount, focused companies attract premium valuations.

India Glycols is a textbook example of a conglomerate discount candidate. A chemical investor has no particular interest in owning a spirits company. A pharma-focused fund cannot easily invest in what is essentially a commodity chemicals business. By separating the three, IGL creates three distinct, investable stories:

– Ennature Bio Pharma: An USFDA-cleared biopharma-ingredients maker in a high-multiple sector. Standalone, it could attract pharma-sector PE multiples rather than commodity-chemicals multiples.

– IGL Spirits: A high-growth spirits business (17% YoY revenue growth, ₹1,025 crore per quarter run rate) in the middle of India’s booming premium and ethanol mandate story. United Spirits trades at very different multiples than an industrial chemical maker.

– Residual IGL: A focused specialty chemicals player with bio-based credentials, competing on India’s green chemistry transition theme.

Per Whalesbook’s analysis: each new entity “will have its own management, strategic priorities, and may attract different types of investors. Separate listings for Ennature Biopharma and IGL Spirits could also lead to distinct market valuations” that together exceed IGL’s current blended market cap.

The USFDA EIR clean bill for Ennature is not a small detail. It positions the biopharma entity to supply regulated markets globally — a qualification that, for a listed pharma company in India, typically commands a valuation premium.

The Bear Case and Risk Factors: Read This Before You Buy

The upside case is real. So are the risks. Investors who go in without understanding the latter deserve the consequences.

NCLT timeline risk. The demerger remains subject to final NCLT sanction. The May 21 hearing is not the end — it’s a hearing where objections from statutory authorities will be addressed. Per ScanX, if objections arise, resolution could push the timeline out by months. Any protracted NCLT process will create uncertainty and potentially pressure the stock.
Credit rating under watch. Per Whalesbook, the company’s credit rating has been placed under watch due to the restructuring. Credit agencies typically monitor how liabilities are apportioned between the demerged entities. An adverse rating action on any of the three resulting companies could affect borrowing costs and market perception.
Legal overhang. India Glycols is navigating a material collection of legal proceedings. These include an arbitration appeal by M/s Texan Minerals and Chemicals LLC in the Singapore High Court, a petition from Uttarakhand Power Corporation before APTEL, customs duty demands related to the Ennature Bio-Pharma division’s imports, and multiple tax disputes. Per Whalesbook: “adverse judgments could lead to significant financial liabilities” that will land on whichever entity inherits them. The distribution of contingent liabilities across the three entities is a key disclosure item to track.
Liquidity risk post-listing. Two newly listed small-to-mid-cap entities (Ennature Bio Pharma and IGL Spirits) will face liquidity discovery when they first trade. Initial pricing can be volatile, and some institutional holders of the parent may not want positions in every resulting company, creating sell pressure at listing.
Execution and management bandwidth. Running three separately listed companies is a different discipline from running one integrated conglomerate. Management depth across the three entities — particularly at Ennature Bio Pharma, where regulatory compliance is operationally intensive — will be critical to watch.

Kaynes Technology Shares Crater amid Cash Flow Crisis

What Investors Should Do

The answer depends on where you are:

If you currently hold INDIAGLYCO: Hold into the demerger. The share entitlement ratio (1:1 for IGL Spirits, 3:1 for Ennature Bio Pharma) means you receive equity in both new entities automatically. There is no reason to sell the parent before the record date to avoid the complexity — you would be giving up the exact value the demerger is designed to unlock. The NCLT hearing on May 21 is an inflection point; monitor the outcome before making any large position adjustments.

If you are considering entering now: The stock has already re-rated significantly from its 52-week low of ₹679. A meaningful portion of the demerger premium is priced in. New entrants should size positions accordingly, treating the current price as partially reflecting anticipated value. This is not a ground-floor opportunity — it is a corporate event play with limited upside unless the new entities are valued materially above consensus on listing.

On the new entities post-listing: When Ennature Bio Pharma and IGL Spirits list on BSE and NSE, assess each on standalone fundamentals. The spirits business has the more immediately legible financials — high growth, large quarterly run rate, clear sector comparables. Ennature Bio Pharma will require more work: its USFDA clean chit is a strong credential, but pharma API businesses require assessment of customer concentration, product pipeline, and regulatory compliance culture. Do not assume that demerger automatically equals premium valuation.

For short-term traders: The May 21 NCLT hearing is a binary catalyst. A smooth hearing without material objections will likely push the stock higher and validate the timeline. A postponement or objection will likely trigger a sell-off. Position sizing ahead of a binary event warrants caution. The RSI near 78 and MFI near 80 suggest the stock is not cheap on a momentum basis, and a negative NCLT outcome could trigger a sharper correction from these levels.

The Bigger Picture

India Glycols’ three-way split is a bet on the idea that clarity of purpose is worth more than scale. In a market that has increasingly rewarded focused businesses with high-quality earnings over diversified conglomerates — and in a regulatory environment where the government is actively pushing bio-based chemicals, pharma exports, and domestic ethanol programs — the timing is arguably right.

The May 21 NCLT hearing is not the finish line. It is the last significant bureaucratic gate before the sprint to listing. The company’s Q4 & Full-Year FY26 earnings conference call — scheduled for May 18, 2026, with CEO Rupark Sarswat and CFO Anand Singhal — will also provide the market with its first comprehensive look at FY26 consolidated numbers ahead of the hearing. Watch that call carefully.

(This article is for informational and journalistic purposes only. It does not constitute investment advice. Readers should consult a SEBI-registered financial advisor before making investment decisions.)